STUB1 and neoplasm: The LIMMA test identified several candidate CHIP mutations whose VAFs were higher in post-NACT tumor DNA than in pre-NACT tumor DNA, but these differences were not significant after p-value adjustment (Figure 4B, Supplementary Table 9).